GLP1R and Parkinson disease: In PD, the inhibition of microglia activation using NLY01 -a glucagon-like peptide-1 receptor (GLP-1R) agonist- modifies the transformation of A1 astrocytes contributing to the inflammatory event, which generates a neuroprotective response (Yun et al. 2018).